Abstract: The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver pre-metastatic niche formation.
Abstract: The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
June 14, 2022
Assignee:
Akston Biosciences Corporation
Inventors:
Thomas M. Lancaster, Todd C. Zion, Thillainayagam Sathiyaseelan, Sylaja Murikipudi
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
August 8, 2018
Date of Patent:
May 24, 2022
Assignee:
ALECTOR LLC
Inventors:
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
Type:
Grant
Filed:
February 17, 2021
Date of Patent:
May 3, 2022
Assignee:
Novo Nordisk A/S
Inventors:
Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw
Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
April 19, 2022
Assignee:
MANNKIND CORPORATION
Inventors:
Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
March 15, 2022
Assignee:
Alpine Immune Sciences, Inc.
Inventors:
Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
Abstract: This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.
Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
February 22, 2022
Assignee:
Eli Lilly and Company
Inventors:
David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.
Type:
Grant
Filed:
November 14, 2019
Date of Patent:
February 22, 2022
Assignee:
Hanmi Pharm. Co., Ltd.
Inventors:
Sung Youb Jung, Young Jin Park, Jong Suk Lee, Jae Hyuk Choi, Chang Ki Lim, Se Chang Kwon
Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
February 15, 2022
Assignee:
Intarcia Therapeutics, Inc.
Inventors:
Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Abstract: A first aspect of the invention relates to a polypeptide compound of formula (I): A-C-B??(I) wherein: A is the A chain of insulin or a functional derivative or variant thereof; B is the B chain of insulin or a functional derivative or variant thereof; C is a peptide of the formula: (X1)p-(X2)n-(X3)q wherein: each X1 and X3 is independently a basic amino acid; each X2 is independently a natural or unnatural amino acid; p is 1 or 2; q is 0, 1 or 2; n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising said polypeptide compound, and therapeutic uses thereof. Another aspect relates to the use of said polypeptide compounds in the preparation of insulin and derivatives thereof.
Type:
Grant
Filed:
September 5, 2017
Date of Patent:
January 25, 2022
Assignee:
CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRA
Inventors:
Dimitrios Gatos, Alexandra Anastasiou, Kleomenis Barlos
Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
January 25, 2022
Assignee:
MEDIMMUNE LIMITED
Inventors:
Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.
Abstract: The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
December 28, 2021
Assignee:
National Jewish Health
Inventors:
Donald Y. M. Leung, Elena Goleva, Lingbo Li
Abstract: A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at positon A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
Type:
Grant
Filed:
June 2, 2016
Date of Patent:
December 28, 2021
Assignee:
Novo Nordisk A/S
Inventors:
Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
December 28, 2021
Assignee:
Alector LLC
Inventors:
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper